Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047656 · ClinicalTrials.gov registry record · Phase 1
To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT02047656 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT02047656, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
This study is designed to enable optimal dose selection of LFF269 for potential future studies by providing additional information about the compounds safety, tolerability, pharmacokinetic and pharmacodynamic profiles.
Interventions
- DRUG LFF269
- DRUG Placebo to LFF269
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047656
The ClinicalTrials.gov registry entry for NCT02047656 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LFF269 is the first listed.
NCT02047656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047656 about?
NCT02047656 is a clinical study titled "To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension". This study is designed to enable optimal dose selection of LFF269 for potential future studies by providing additional information about the compounds safety, tolerability, pharmacokinetic and pharmacodynamic profiles.
What is the current status of trial NCT02047656?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2013-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02047656?
The interventions under investigation include: LFF269 (DRUG), Placebo to LFF269 (DRUG).
Who is sponsoring clinical trial NCT02047656?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.